Project description
Enhancing screening in the drug discovery pipeline will boost successful passage through it
Drug approval still takes about 14 years and the failure rate during clinical trials is about 85 %. At each phase, many targets fail due to safety and efficacy issues, in large part because research models of disease do not adequately model all human factors. SINERGIA will focus on optimising the use of four cutting-edge technologies that support in vivo modelling of drug mechanisms and effects. It brings together academic research entities, contract research organisations, and biotech and pharmaceutical companies. Implementation of better disease models in the drug discovery pipeline could significantly enhance the success and speed at which new candidates are brought from the bench to the bedside.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicinephysiology
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
20133 Milano
Italy
See on map
Participants (9)
4051 Basel
See on map
6200 MD Maastricht
See on map
656 91 Brno
See on map
52074 Aachen
See on map
CH-6500 Bellinzona
See on map
20014 Nerviano Mi
See on map
5611 ZS Eindhoven
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20158 Milano
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34132 Trieste
See on map